熱門資訊> 正文
Anixa Biosciences与克利夫兰诊所执行数据传输协议
2025-11-05 21:58
- Anixa Biosciences (ANIX) on Wednesday said that it has executed a data transfer agreement with the Cleveland Clinic as a key step in the process of transferring the breast cancer vaccine clinical trial data and sponsorship to Anixa for future clinical development.
- With enrollment completed and encouraging immune response data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and will assume full sponsorship of the IND.
- The IND, currently sponsored by Cleveland Clinic, is in the process of being transferred to Anixa.
- The DTA will allow for the transfer of all relevant data and information, collected and generated from the Phase 1 clinical trial, to Anixa.
More on Anixa Biosciences
- Anixa Biosciences announces issuance of additional U.S. patent for CAR-T technology
- Seeking Alpha’s Quant Rating on Anixa Biosciences
- Historical earnings data for Anixa Biosciences
- Financial information for Anixa Biosciences
推薦文章
美股機會日報 | 貴金屬史詩級牛市！黃金年內飆升70%，漲破4500美元關口；英特爾遭利空一度跌逾5%
聖誕節休市提醒：港股休市兩天半，美股休市一天半
谷歌年初在人工智能競賽中落后，卻在2025年末登頂行業榜首
華盛早報 | 美聯儲主席熱門人選哈塞特：降息節奏仍需加速！英偉達稱春節前向中國交付H200芯片；中芯國際對部分產能漲價10%
12月24日外盤頭條：美國消費者信心連續第五個月下滑 金銀連續兩日刷新歷史新高 特朗普提美聯儲主席必要條件
美聯儲主席候選人哈塞特：美國在降息方面已嚴重滯后
美股機會日報 | 黃金再創新高！現貨黃金逼近4500美元關口；甲骨文CEO埃里森為派拉蒙提供鉅額資金擔保
資金覆盤 | 北水淨買入港股6.11億港元，加倉阿里超13億港元，賣出騰訊超10億港元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
